The Administrative Core, led by Dr. Frederick Lang (Director) and Dr. Juan Fueyo (Co-Director), provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are to: Oversee and administer all SPORE activities. Oversee all SPORE Projects and Core activities. Oversee the Developmental Research and Career Development Programs. Promote integration and communication between the SPORE, the Brain Cancer Program, and the Cancer Center Support Grant. Ensure compliance with institutional, governmental, and NCI regulations. Communicate and consult with the NCI program officer and other staff to ensure timely preparation and submission of reports, publications, and Important events that affect management of the SPORE. Oversee and administer all fiscal and budgetary activities of the SPORE. Manage and provide quality assurance, including data quality control, in cooperation with the Biostatistics and Bioinformatics Core. Coordinate meetings of the Executive Committee, Internal and External Advisory Boards, monthly investigator meetings, lectures, and symposia. Ensure compliance with and improvement of policies for recruitment of women and minorities. Coordinate with other Brain Cancer SPORE programs and investigators, as well as other organ site SPORE programs, to promote research communication in meetings, distribution of materials, electronic communications, and evaluation of progress reports.
The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in brain cancer.
|Gressot, Loyola V; Doucette, Tiffany A; Yang, Yuhui et al. (2015) Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 136:2047-54|
|Chen, James C; Alvarez, Mariano J; Talos, Flaminia et al. (2014) Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 159:402-14|
|Schrand, Brett; Berezhnoy, Alexey; Brenneman, Randall et al. (2014) Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2:867-77|
|Lang, Frederick F; Barker 2nd, Fred G (2014) A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium. J Neurooncol 119:593-600|
|Olar, Adriana; Aldape, Kenneth D (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165-77|
|Singh, Mamata; Leasure, Justin M; Chronowski, Christopher et al. (2014) FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res 20:3884-95|
|Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5|
|Conrad, Charles A; Fueyo, Juan; Gomez-Manzano, Candelaria (2014) Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16:1025-6|
|Zhao, Jun; Wallace, Michael; Melancon, Marites P (2014) Cancer theranostics with gold nanoshells. Nanomedicine (Lond) 9:2041-57|
|Jiang, Hong; Clise-Dwyer, Karen; Ruisaard, Kathryn E et al. (2014) Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9:e97407|
Showing the most recent 10 out of 70 publications